EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Ferroptosis and the cGAS–STING pathway into precision nano-immuno-theranostics: A mechanistic paradigm for reversing drug resistance in hepatocellular carcinoma

Alaa Elmetwalli

Drug Resistance Updates · 2026

DOI: 10.1016/j.drup.2025.101326 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Resistance Updates, 2026. Verfasst von Alaa Elmetwalli. Beteiligte Einrichtung: Prince Fahad bin Sultan Chair for Biomedical Research, University of Tabuk, Tabuk, Saudi Arabia. Electronic address: aelmetwalli@ut.edu.sa. Hauptthemen laut MEDLINE: Ferroptosis, Carcinoma, Hepatocellular, Liver Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 573 Literaturangaben. Gefördert von: University of Tabuk.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) represents a formidable therapeutic challenge, with intrinsic and acquired resistance mechanisms severely limiting treatment efficacy and contributing to dismal patient outcomes. This comprehensive review examines the emerging paradigm of precision nano-immuno-theranostics, specifically focusing on ferroptosis-STING coupled platforms as innovative strategies for overcoming multifaceted HCC resistance. This study systematically analyzes five key nanotechnology approaches: lipid nanoparticles (LNPs) for dual-cargo delivery, GPC3-targeted immunotherapeutic platforms, multimodal theranostic systems, sonodynamic therapy constructs, and spatial transcriptomics-guided precision designs. The strategic integration of ferroptosis induction-an iron-dependent cell death mechanism uniquely suited to the iron-rich hepatic microenvironment-with cGAS-STING pathway activation establishes a bidirectional synergistic loop wherein ferroptotic tumor death generates endogenous STING activation, which reciprocally sensitizes cancer cells to ferroptosis. This dual-targeting approach converts immunologically "cold" HCC tumors into inflamed "hot" therapeutic targets, achieving 78-91 % tumor growth inhibition and 4.2-4.8-fold increases in CD8 + tumor-infiltrating lymphocytes in preclinical models, substantially exceeding conventional monotherapies (sorafenib: 45-52 %; checkpoint inhibitors: 35-48 %). Mechanistically, ferroptosis-STING coupling simultaneously addresses three critical resistance modalities: chemoresistance through GPX4/NRF2 axis collapse, immunoresistance via tumor microenvironment reprogramming, and metabolic resistance by disrupting HIF-1α/STAT3-mediated adaptation. Despite compelling preclinical evidence, translation to clinical practice faces substantial challenges in manufacturing scalability, regulatory approval pathways for combination nanotechnology products, biomarker-driven patient stratification, and long-term safety assessment. This review critically evaluates current nano-immuno-theranostic platforms, provides quantitative comparative analysis against existing HCC therapies, identifies critical translational gaps, and proposes strategic solutions spanning adaptive regulatory frameworks, continuous manufacturing innovations, and precision medicine integration. The convergence of nanotechnology, immunotherapy, and multi-omic profiling offers unprecedented opportunities for developing next-generation HCC therapeutics capable of dismantling the complex resistance networks that characterize this aggressive malignancy, with first-in-human trials anticipated in 2025-2027 and potential regulatory approval trajectories extending to 2030.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisCarcinoma, HepatocellularLiver NeoplasmsDrug Resistance, NeoplasmMembrane ProteinsNucleotidyltransferasesAntineoplastic AgentsHumansImmunotherapyTheranostic NanomedicineNanoparticlesTumor MicroenvironmentSignal TransductionAnimalsPrecision MedicineSTING ProteinCyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase

Stichwörter der Autor:innen

Drug resistanceHCCIron metabolismLipid nanoparticlesNanomedicinecGAS–STING pathwayferroptosisimmunotherapytheranostics

Substanzen

Membrane ProteinsNucleotidyltransferasesAntineoplastic AgentsSTING1 protein, humanSTING ProteincGAS protein, humanCyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase

Autor:innen und Institutionen

  • Prince Fahad bin Sultan Chair for Biomedical Research, University of Tabuk, Tabuk, Saudi Arabia. Electronic address: aelmetwalli@ut.edu.sa.

Förderung

  • University of Tabuk

Zitieren

APA

Elmetwalli, A. (2026). Ferroptosis and the cGAS–STING pathway into precision nano-immuno-theranostics: A mechanistic paradigm for reversing drug resistance in hepatocellular carcinoma. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2025.101326

Vancouver

Elmetwalli A. Ferroptosis and the cGAS–STING pathway into precision nano-immuno-theranostics: A mechanistic paradigm for reversing drug resistance in hepatocellular carcinoma. Drug Resistance Updates. 2026. doi:10.1016/j.drup.2025.101326

BibTeX
@article{Elmetwalli2026,
  author = {Elmetwalli, Alaa},
  title = {Ferroptosis and the cGAS–STING pathway into precision nano-immuno-theranostics: A mechanistic paradigm for reversing drug resistance in hepatocellular carcinoma},
  journal = {Drug Resistance Updates},
  year = {2026},
  doi = {10.1016/j.drup.2025.101326}
}
Kostenlos starten →